Skip to main
  1. Stocks
  2. MediWound
  3. Forecast
MDWD

MediWound (MDWD) Stock Forecast & Price Target

MediWound (MDWD) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediWound is supported by a differentiated wound-care portfolio that combines near-term commercial visibility from NexoBrid with a longer-duration growth option in EscharEx, while 2Q26 revenue of $3.1M beat expectations and full-year 2026 guidance of $24-26M was reaffirmed despite government contract timing uncertainty. The company’s outlook is strengthened by the 10-year BARDA contract valued at up to $197M, recovering NexoBrid shipments, and expected European regulatory clearance in 2H26 for the expanded manufacturing facility, which should support execution without altering the underlying guidance. Longer term, EscharEx remains the key value driver with VALUE Phase III topline data now expected in 2H27 and expansion into DFU and pressure ulcers under evaluation, giving the story meaningful upside beyond the current burn-care franchise.

Bears say

MediWound is facing a weak fundamental setup as NexoBrid’s capacity constraints persist, with EMA-requested modifications not expected to be completed until YE26 and facility approval slipping into 2H27, delaying commercial scale and forcing at-risk production to absorb demand. The reimbursement backdrop is also poor, since EU countries do not approve favorable reimbursement for NexoBrid in medium to severe burn wounds, contributing to weak revenue generation and continued unprofitability. On top of that, EscharEx’s initial revenues have been pushed further into 2028, and any disappointment in its P3 efficacy would further undermine the investment case.

MediWound (MDWD) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.

MediWound (MDWD) Analyst Forecast & Price Prediction

Get the latest MediWound (MDWD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MediWound (MDWD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediWound (MDWD) Forecast

Analysts have given MediWound (MDWD) a Buy based on their latest research and market trends.

According to 2 analysts, MediWound (MDWD) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediWound (MDWD)


MediWound (MDWD) Analyst Forecast & Price Prediction

Get the latest MediWound (MDWD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MediWound (MDWD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MDWD stock data and trends